Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Canagliflozin
Drug ID BADD_D00344
Description Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083].
Indications and Usage Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
Marketing Status Prescription
ATC Code A10BK02
DrugBank ID DB08907
KEGG ID D09592
MeSH ID D000068896
PubChem ID 24812758
TTD Drug ID D08DFX
NDC Product Code 50090-5034; 55154-1425; 50090-5029; 70966-0001; 12578-615; 50923-1216; 50458-141; 55111-978; 50458-140; 42385-735; 17314-575; 59651-065; 50090-4364; 46708-886; 14445-017; 17314-577; 12578-611; 55154-1426; 50090-5033
Synonyms Canagliflozin | Invokana | Canagliflozin Hemihydrate | Canagliflozin, Anhydrous | 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
Chemical Information
Molecular Formula C24H25FO5S
CAS Registry Number 842133-18-0
SMILES CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Acetonaemia14.01.01.0120.001149%Not Available
Acidosis14.01.03.0020.006510%
Acne23.02.01.001--Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.01.003--
Albumin urine present13.13.02.0120.000766%Not Available
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Amylase increased13.05.01.0090.000766%
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anion gap increased13.02.01.0140.003447%Not Available
Anosmia22.04.03.006; 17.04.04.0010.000766%
Anxiety19.06.02.002--
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.001--Not Available
Arterial thrombosis24.01.01.0020.000766%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
The 1th Page    1 2 3 4 5    Next   Last    Total 18 Pages